The aim of the study was to evaluate the levels of apelin and ghrelin, which are two peptide hormones, in patients with relapsing-remitting MS (RRMS) receiving natalizumab and fingolimod compared to healthy controls.<h4>Methods</h4>We enrolled forty-nine patients with RRMS and thirty-eight healthy individuals. The gene discussed is APLN; the disease is relapsing-remitting multiple sclerosis.